Risk Factors of Epistaxis Recurrence in Adults
Launched by UNIVERSITY HOSPITAL, GRENOBLE · Oct 22, 2024
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on understanding the risk factors that may cause nosebleeds, also known as epistaxis, to happen again in adults. The researchers will look at patients who were treated in the Emergency Department for nosebleeds between January 2022 and July 2023. They will review medical records and contact patients to gather information about whether their nosebleeds returned after treatment. By studying various factors, the team aims to find out which ones might increase the chances of nosebleeds happening again.
To be eligible for this trial, participants must be adults over 18 years old who were admitted to the Emergency Department for a nosebleed during the study period. Importantly, individuals who do not want to participate in the study will be excluded. If you decide to join, you can expect to answer some questions about your health and the recurrence of nosebleeds. This study is important because it could help doctors understand how to better treat and prevent future nosebleeds for patients like you.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient who is admitted at the emergency department between 01/2022 and 07/2023 for nose bleeding.
- • Age over 18 yo
- Exclusion Criteria:
- • Opposition to be included
- • Patient who has not his willness to provide opposition to participate.opposition
About University Hospital, Grenoble
The University Hospital of Grenoble is a leading academic medical center dedicated to advancing healthcare through innovative clinical research and comprehensive patient care. As a prominent sponsor of clinical trials, the hospital leverages its expertise in various medical disciplines to facilitate cutting-edge studies that aim to improve treatment outcomes and enhance patient safety. With a strong commitment to collaboration, the University Hospital of Grenoble engages in partnerships with academic institutions, industry leaders, and regulatory bodies to drive scientific discovery and translate research findings into clinical practice. Its state-of-the-art facilities and multidisciplinary teams ensure rigorous adherence to ethical standards and regulatory guidelines, fostering an environment where groundbreaking research can thrive.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
La Tronche, Isere, France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported